351 related articles for article (PubMed ID: 25879426)
21. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
[TBL] [Abstract][Full Text] [Related]
22. The bivalirudin paradox: high evidence, low use.
De Servi S; Mariani G; Mariani M; D'Urbano M
J Cardiovasc Med (Hagerstown); 2013 May; 14(5):334-41. PubMed ID: 23442811
[TBL] [Abstract][Full Text] [Related]
23. Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials.
Shah R; Matin K; Rogers KC; Rao SV
Catheter Cardiovasc Interv; 2017 Aug; 90(2):196-204. PubMed ID: 27862911
[TBL] [Abstract][Full Text] [Related]
24. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
Abtahian F; Waldo S; Jang IK
Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
26. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes.
Stone GW; Mehran R; Steg PG
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):225-227. PubMed ID: 25616930
[No Abstract] [Full Text] [Related]
27. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
[TBL] [Abstract][Full Text] [Related]
28. A meta-analysis and cost-minimization analysis of bivalirudin versus heparin in high-risk patients for percutaneous coronary intervention.
Sun KX; Cui B; Cao SS; Wang WJ; Yu F; Wang JW; Ding Y
Pharmacol Res Perspect; 2021 May; 9(3):e00774. PubMed ID: 33939886
[TBL] [Abstract][Full Text] [Related]
29. The clinical and economic impact of bivalirudin for percutaneous coronary intervention.
Malik N; Gershlick AH
Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):699-706. PubMed ID: 24219045
[TBL] [Abstract][Full Text] [Related]
30. Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
Bangalore S; Cohen DJ; Kleiman NS; Regev-Beinart T; Rao SV; Pencina MJ; Mauri L;
Circ Cardiovasc Interv; 2011 Oct; 4(5):463-73. PubMed ID: 21972401
[TBL] [Abstract][Full Text] [Related]
31. Clinical applications of bivalirudin in the cardiac catheterization laboratory.
Thompson KA; Philip KJ; Schwarz ER
J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):140-9. PubMed ID: 21097669
[TBL] [Abstract][Full Text] [Related]
32. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
33. Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction.
Faulkenberg KD; Beavers JC; Finks SW
Ann Pharmacother; 2016 Feb; 50(2):141-51. PubMed ID: 26681442
[TBL] [Abstract][Full Text] [Related]
34. The comparative safety and effectiveness of bivalirudin versus heparin monotherapy in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan cardiovascular consortium.
Sukul D; Seth M; Schreiber T; Khandelwal A; Cannon LA; LaLonde TA; Gurm HS
Catheter Cardiovasc Interv; 2017 Nov; 90(5):724-732. PubMed ID: 28303632
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
[TBL] [Abstract][Full Text] [Related]
36. Pharmacoeconomics of anticoagulants in acute coronary syndrome and percutaneous coronary intervention.
Huston SA; Hawkins D
Curr Pharm Des; 2008; 14(12):1197-204. PubMed ID: 18473867
[TBL] [Abstract][Full Text] [Related]
37. Bivalirudin use and one-month outcome in the context of contemporary antiplatelet treatment: insights from the Greek Antiplatelet Registry.
Alexopoulos D; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Karayannis G; Angelidis C; Stavrou K; Vavuranakis M; Goudevenos JA; Stefanadis C;
Cardiovasc Ther; 2014 Jun; 32(3):120-6. PubMed ID: 24512682
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
[TBL] [Abstract][Full Text] [Related]
39. Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin?
Silvain J; Montalescot G
Arch Cardiovasc Dis; 2012 May; 105(5):259-61. PubMed ID: 22709466
[No Abstract] [Full Text] [Related]
40. Gender-based outcomes of bivalirudin versus heparin in patients undergoing percutaneous coronary interventions: Meta-analysis of randomized controlled trials.
Mina GS; Firouzbakht T; Modi K; Dominic P
Catheter Cardiovasc Interv; 2017 Nov; 90(5):735-742. PubMed ID: 28339139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
